DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Next Generation Cancer Diagnostics Market Size & Forecast By Technology, By Function, By Cancer Type, By Application And Trend Analysis From 2015 To 2022" report to their offering.
Global next generation cancer diagnostics market is anticipated to reach USD 20.25 billion by 2022 growing at an estimated CAGR of 32.0% from 2015 to 2022. Rising incidence of oncology diseases is anticipated to drive the demand for next generation cancer diagnostic tests that are expected to enhance early diagnosis and efficient prognosis of various forms of cancers is a factor expected to positively influence sector growth over the forecast period.
Cancer diagnostics industry is estimated to witness lucrative growth over the forecast period majorly due to rising number of technologically advanced products in the field of companion diagnostics, providing more precise testing results combined with therapeutic monitoring early diagnosis of cancer. Moreover, there is a significant shift observed from traditional laboratory testing to rapid point of care testing, which fuels growth in the market owing to expected commercialization of technologically advanced range of products including diagnostic kits, instruments, and reagents.
Furthermore, supportive government initiatives in order to increase the number of research projects with respect to oncology and preventative diagnosis is expected to be attributive for growth in this sector over the coming years. Additionally, application of tumor diagnostics in epigenetic analysis and CTC enumeration for monitoring tumorigenesis is expected to support projected growth over the forecast period.
Companies Profiled:
- Johnson & Johnson
- Novartis AG
- Roche Holding AG
- Philips Electronics NV
- Abbott Laboratories
- GE Healthcare
- Thermo Fisher Scientific Inc.
- Agilent Technologies Inc
- Perkin Elmer Inc.
- Illumina Inc.
- Qiagen
- Hologic Inc.
- Myriad Genetics Inc.
- Almac Group Ltd.
- Cepheid
- Exosome Diagnostics Inc.
- Genomic Health Inc.
- Opko Health Inc.
-
Sysmex
Key Topics Covered:
1. Methodology and Scope
2. Executive Summary
3. Next Generation Cancer Diagnostics Industry Outlook
4. Next Generation Cancer Diagnostics Technology Outlook
5. Next Generation Cancer Diagnostics Outlook, By Function
6. Next Generation Cancer Diagnostics Application Outlook
7. Next Generation Cancer Diagnostics Outlook, By Cancer Type
8. Next Generation Cancer Diagnostics Regional Outlook
9. Competitive Landscape
For more information visit http://www.researchandmarkets.com/research/9m54jg/next_generation
